KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Net Cash Flow (2016 - 2025)

West Pharmaceutical Services' Net Cash Flow history spans 17 years, with the latest figure at $163.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 895.73% year-over-year to $163.3 million; the TTM value through Dec 2025 reached $283.8 million, up 181.58%, while the annual FY2025 figure was $283.8 million, 181.58% up from the prior year.
  • Net Cash Flow for Q4 2025 was $163.3 million at West Pharmaceutical Services, up from $122.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $163.3 million in Q4 2025 and bottomed at -$243.4 million in Q1 2024.
  • The 5-year median for Net Cash Flow is $34.1 million (2022), against an average of $9.5 million.
  • The largest annual shift saw Net Cash Flow tumbled 1522.67% in 2024 before it skyrocketed 895.73% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $77.2 million in 2021, then soared by 63.86% to $126.5 million in 2022, then tumbled by 146.8% to -$59.2 million in 2023, then skyrocketed by 127.7% to $16.4 million in 2024, then surged by 895.73% to $163.3 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Net Cash Flow are $163.3 million (Q4 2025), $122.4 million (Q3 2025), and $87.0 million (Q2 2025).